GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (CHIX:PRTCl) » Definitions » EV-to-EBIT

PureTech Health (CHIX:PRTCL) EV-to-EBIT : 2.46 (As of Jun. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is PureTech Health EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PureTech Health's Enterprise Value is £66.21 Mil. PureTech Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was £26.96 Mil. Therefore, PureTech Health's EV-to-EBIT for today is 2.46.

The historical rank and industry rank for PureTech Health's EV-to-EBIT or its related term are showing as below:

CHIX:PRTCl' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.59   Med: -2.62   Max: 59.05
Current: 2.46

During the past 13 years, the highest EV-to-EBIT of PureTech Health was 59.05. The lowest was -22.59. And the median was -2.62.

CHIX:PRTCl's EV-to-EBIT is ranked better than
57.23% of 470 companies
in the Biotechnology industry
Industry Median: 8.875 vs CHIX:PRTCl: 2.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PureTech Health's Enterprise Value for the quarter that ended in Dec. 2024 was £86.67 Mil. PureTech Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was £26.96 Mil. PureTech Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 31.11%.


PureTech Health EV-to-EBIT Historical Data

The historical data trend for PureTech Health's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health EV-to-EBIT Chart

PureTech Health Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.46 -12.82 -6.83 -15.95 3.04

PureTech Health Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.83 - -15.95 - 3.04

Competitive Comparison of PureTech Health's EV-to-EBIT

For the Biotechnology subindustry, PureTech Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PureTech Health's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PureTech Health's EV-to-EBIT falls into.


;
;

PureTech Health EV-to-EBIT Calculation

PureTech Health's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=66.206/26.962
=2.46

PureTech Health's current Enterprise Value is £66.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was £26.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PureTech Health  (CHIX:PRTCl) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PureTech Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=26.962/86.666604
=31.11 %

PureTech Health's Enterprise Value for the quarter that ended in Dec. 2024 was £86.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PureTech Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was £26.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PureTech Health EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PureTech Health's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


PureTech Health Business Description

Traded in Other Exchanges
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

PureTech Health Headlines

No Headlines